Saran Saund - Sep 3, 2021 Form 4 Insider Report for Oncotelic Therapeutics, Inc. (OTLC)

Role
Chief Business Officer
Signature
/s/ Saran Saund
Stock symbol
OTLC
Transactions as of
Sep 3, 2021
Transactions value $
$0
Form type
4
Date filed
9/8/2021, 05:00 PM
Previous filing
Jul 16, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLC Stock Options Award $0 +675K $0.00 675K Sep 3, 2021 Common Stock 675K $0.14 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock Options vest as follows: (i) 50% of the options will vest upon the consummation of a qualifying joint venture agreement, licensing agreement, or acquisition transaction (a "Corporate Transaction"); (ii) The remaining 50% on the one-year anniversary of the consummation of a Corporate Transaction.